# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 27.4 | 76.7 | (47.4-117.2) |  | Male | 24 | 17.8 | 134.5 | (86.1-200.1) |
| Female | 12 | 10.0 | 120.4 | (62.1-210.3) |  | Female | 13 | 13.7 | 95.0 | (50.5-162.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.3 | 113.5 | (41.4-247.0) |  | Male | 6 | 5.6 | 106.6 | (38.9-232.0) |
| Female | 5 | 4.3 | 115.1 | (37.1-268.5) |  | Female | 5 | 4.5 | 111.5 | (35.9-260.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 12 | 15.9 | 75.3 | (38.8-131.5) |
| Female | 137 | 107.7 | 127.2 | (106.8-150.3) |  | Female | 11 | 13.8 | 79.5 | (39.6-142.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 13.2 | 67.9 | (31.0-129.0) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 5 | 5.8 | 86.5 | (27.9-201.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 30.1 | 116.3 | (81.0-161.7) |  |  |  |  |  |  |
| Female | 32 | 30.4 | 105.2 | (71.9-148.5) |  | Female | 12 | 9.6 | 125.6 | (64.8-219.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.4 | 67.1 | (21.6-156.7) |  | Male | 11 | 9.8 | 112.2 | (55.9-200.8) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 8 | 10.1 | 79.6 | (34.3-156.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 117 | 96.0 | 121.8 | (100.8-146.0) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 15.5 | 109.9 | (64.0-176.0) |  | Male | 6 | 6.5 | 92.4 | (33.7-201.1) |
| Female | 6 | 8.6 | 69.8 | (25.5-151.9) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.3 | 161.7 | (64.8-333.2) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 11.0 | 63.9 | (25.6-131.6) |  | Male | 6 | 7.1 | 85.0 | (31.1-185.1) |
| Female | 11 | 8.1 | 135.8 | (67.7-243.0) |  | Female | 19 | 19.2 | 99.2 | (59.7-154.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.8 | 71.2 | (28.5-146.7) |  |  |  |  |  |  |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 22 | 24.4 | 90.2 | (56.5-136.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 49.2 | 81.2 | (58.0-110.6) |  | Male | 376 | 366.6 | 102.6 | (92.5-113.5) |
| Female | 47 | 51.5 | 91.2 | (67.0-121.3) |  | Female | 384 | 367.0 | 104.6 | (94.4-115.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

316

# Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 61 | 52.5 | 116.2 | (88.9-149.3) |  | Male | 25 | 35.8 | 69.9 | (45.2-103.2) |
| Female | 21 | 20.2 | 104.0 | (64.3-158.9) |  | Female | 14 | 30.7 | 45.6 | (24.9-76.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 15 | 11.4 | 132.0 | (73.8-217.8) |  | Male | 9 | 10.7 | 83.8 | (38.3-159.1) |
| Female | 13 | 9.5 | 136.8 | (72.8-233.9) |  | Female | 4 | 9.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 26 | 31.7 | 82.0 | (53.5-120.1) |
| Female | 234 | 221.2 | 105.8 | (92.7-120.2) |  | Female | 32 | 28.6 | 111.8 | (76.4-157.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 25.4 | 63.1 | (36.0-102.4) |
| Female | 9 | 8.2 | 109.7 | (50.1-208.3) |  | Female | 8 | 11.9 | 67.0 | (28.9-132.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 60 | 57.2 | 104.8 | (80.0-134.9) |  |  |  |  |  |  |
| Female | 56 | 60.8 | 92.1 | (69.6-119.6) |  | Female | 18 | 20.1 | 89.4 | (52.9-141.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 14.1 | 92.1 | (49.0-157.4) |  | Male | 21 | 18.7 | 112.5 | (69.6-171.9) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 25 | 20.4 | 122.8 | (79.4-181.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 146 | 181.6 | 80.4 | (67.9-94.5) |
| Female | 5 | 4.8 | 104.2 | (33.6-243.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 30.1 | 119.6 | (83.7-165.5) |  | Male | 18 | 12.5 | 144.2 | (85.4-227.9) |
| Female | 16 | 17.8 | 89.9 | (51.4-146.1) |  | Female | 9 | 7.9 | 114.2 | (52.1-216.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 8.3 | 60.1 | (19.4-140.2) |  | Male | 12 | 11.3 | 105.8 | (54.6-184.8) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 22.2 | 85.5 | (51.4-133.5) |  | Male | 17 | 15.2 | 112.1 | (65.3-179.5) |
| Female | 13 | 17.3 | 75.3 | (40.1-128.8) |  | Female | 53 | 46.6 | 113.7 | (85.1-148.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 18.6 | 102.0 | (61.4-159.3) |  |  |  |  |  |  |
| Female | 5 | 6.4 | 77.6 | (25.0-181.2) |  | Female | 41 | 50.5 | 81.2 | (58.3-110.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 93 | 95.6 | 97.3 | (78.5-119.2) |  | Male | 667 | 715.5 | 93.2 | (86.3-100.6) |
| Female | 109 | 105.4 | 103.4 | (84.9-124.7) |  | Female | 750 | 765.7 | 98.0 | (91.1-105.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

317

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 10.5 | 66.4 | (26.6-136.8) |  | Male | 4 | 7.0 | nc | (nc-nc) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 2 | 5.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 7 | 6.3 | 111.6 | (44.7-230.0) |
| Female | 34 | 47.4 | 71.8 | (49.7-100.3) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 11.8 | 127.5 | (71.3-210.3) |  |  |  |  |  |  |
| Female | 16 | 12.2 | 131.1 | (74.9-212.9) |  | Female | 5 | 4.2 | 118.7 | (38.2-277.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 8 | 3.8 | 208.1 | (89.6-410.0) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 6 | 4.0 | 149.9 | (54.7-326.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 29 | 39.4 | 73.7 | (49.3-105.8) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 8 | 3.7 | 216.5 | (93.2-426.6) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 2 | 8.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.0 | 125.2 | (40.3-292.1) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 9 | 10.9 | 82.8 | (37.8-157.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 19.3 | 109.0 | (67.4-166.6) |  | Male | 134 | 145.8 | 91.9 | (77.0-108.9) |
| Female | 16 | 21.8 | 73.3 | (41.8-119.0) |  | Female | 134 | 156.2 | 85.8 | (71.9-101.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

318

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 38 | 29.7 | 128.0 | (90.6-175.7) |  | Male | 17 | 18.2 | 93.2 | (54.3-149.3) |
| Female | 15 | 10.1 | 148.3 | (82.9-244.6) |  | Female | 14 | 13.8 | 101.6 | (55.5-170.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.0 | 158.4 | (68.2-312.2) |  | Male | 10 | 5.9 | 170.7 | (81.7-314.0) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 2 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 17 | 16.2 | 104.9 | (61.1-167.9) |
| Female | 94 | 109.9 | 85.5 | (69.1-104.6) |  | Female | 8 | 13.9 | 57.4 | (24.7-113.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 12.5 | 119.6 | (66.9-197.3) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 6 | 5.9 | 101.9 | (37.2-221.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 30.8 | 107.2 | (73.8-150.5) |  |  |  |  |  |  |
| Female | 39 | 30.3 | 128.7 | (91.5-175.9) |  | Female | 9 | 9.8 | 92.0 | (42.0-174.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.5 | 93.1 | (37.3-191.8) |  | Male | 10 | 10.2 | 98.2 | (47.0-180.6) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 12 | 10.1 | 118.5 | (61.2-207.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 87 | 92.4 | 94.1 | (75.4-116.1) |
| Female | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 14.9 | 107.3 | (61.3-174.2) |  | Male | 6 | 6.8 | 88.3 | (32.3-192.3) |
| Female | 15 | 8.8 | 171.2 | (95.7-282.3) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.4 | 114.1 | (36.8-266.2) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 11.2 | 80.3 | (36.7-152.5) |  | Male | 7 | 6.3 | 110.5 | (44.3-227.8) |
| Female | 18 | 8.0 | 226.0 | (133.9-357.3) |  | Female | 18 | 18.9 | 95.0 | (56.3-150.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 9.7 | 144.5 | (78.9-242.5) |  |  |  |  |  |  |
| Female | 5 | 3.2 | 155.9 | (50.2-363.7) |  | Female | 20 | 25.3 | 79.2 | (48.3-122.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 79 | 52.7 | 150.0 | (118.7-186.9) |  | Male | 412 | 370.2 | 111.3 | (100.8-122.6) |
| Female | 82 | 53.7 | 152.6 | (121.4-189.4) |  | Female | 401 | 372.6 | 107.6 | (97.4-118.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

319

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.2 | 116.5 | (42.5-253.6) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 15 | 22.0 | 68.1 | (38.1-112.3) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 5.7 | 123.5 | (49.5-254.4) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 7 | 1.8 | 380.8 | (152.6-784.7) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 15 | 18.7 | 80.3 | (44.9-132.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 5.0 | 120.1 | (43.8-261.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 9.3 | 96.4 | (44.0-183.0) |  | Male | 61 | 69.8 | 87.4 | (66.8-112.2) |
| Female | 8 | 9.9 | 81.1 | (34.9-159.8) |  | Female | 51 | 72.4 | 70.5 | (52.5-92.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

320

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 4.1 | 148.0 | (54.1-322.2) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 14 | 14.6 | 95.7 | (52.3-160.6) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 14 | 14.2 | 98.3 | (53.7-164.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

321

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 4 | 11.8 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 8 | 9.0 | 88.7 | (38.2-174.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

322

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 33.3 | 105.2 | (73.2-146.3) |  | Male | 14 | 21.7 | 64.6 | (35.3-108.5) |
| Female | 9 | 13.1 | 68.7 | (31.4-130.4) |  | Female | 21 | 19.0 | 110.8 | (68.5-169.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 6.5 | 153.1 | (73.3-281.7) |  | Male | 5 | 6.7 | 74.3 | (23.9-173.4) |
| Female | 9 | 5.6 | 161.1 | (73.5-305.7) |  | Female | 5 | 5.9 | 85.2 | (27.4-198.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 20 | 19.3 | 103.7 | (63.3-160.1) |
| Female | 149 | 141.2 | 105.5 | (89.2-123.9) |  | Female | 21 | 18.4 | 114.4 | (70.8-174.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 14.8 | 101.5 | (56.8-167.4) |
| Female | 8 | 5.1 | 155.8 | (67.1-307.0) |  | Female | 3 | 7.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 45 | 36.2 | 124.3 | (90.6-166.3) |  |  |  |  |  |  |
| Female | 38 | 39.0 | 97.5 | (69.0-133.8) |  | Female | 15 | 12.7 | 118.3 | (66.2-195.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 8.4 | 106.9 | (48.8-202.9) |  | Male | 12 | 11.4 | 105.4 | (54.4-184.1) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 18 | 13.1 | 137.1 | (81.2-216.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 92 | 102.0 | 90.2 | (72.7-110.7) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 17.9 | 128.2 | (81.2-192.3) |  | Male | 8 | 7.8 | 102.4 | (44.1-201.8) |
| Female | 4 | 11.4 | nc | (nc-nc) |  | Female | 11 | 5.0 | 220.3 | (109.8-394.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 5.0 | 100.8 | (32.5-235.2) |  | Male | 5 | 5.8 | 86.4 | (27.9-201.7) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 13.4 | 89.3 | (46.1-156.0) |  | Male | 12 | 8.6 | 139.2 | (71.9-243.2) |
| Female | 10 | 10.4 | 95.8 | (45.8-176.1) |  | Female | 24 | 28.1 | 85.5 | (54.8-127.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 11.0 | 90.8 | (43.5-167.1) |  |  |  |  |  |  |
| Female | 6 | 4.1 | 146.0 | (53.3-317.7) |  | Female | 26 | 31.9 | 81.5 | (53.2-119.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 52 | 58.7 | 88.7 | (66.2-116.3) |  | Male | 417 | 427.2 | 97.6 | (88.5-107.4) |
| Female | 61 | 70.1 | 87.1 | (66.6-111.8) |  | Female | 470 | 487.1 | 96.5 | (88.0-105.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

323

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 17.7 | 45.1 | (19.4-88.9) |  | Male | 15 | 10.9 | 137.6 | (76.9-226.9) |
| Female | 5 | 6.2 | 80.2 | (25.8-187.2) |  | Female | 16 | 8.3 | 192.8 | (110.1-313.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 5 | 3.5 | 141.1 | (45.5-329.2) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 10 | 9.8 | 102.3 | (49.0-188.1) |
| Female | 83 | 69.3 | 119.7 | (95.3-148.4) |  | Female | 11 | 8.6 | 127.2 | (63.4-227.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 7.7 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 18.7 | 64.1 | (33.1-112.0) |  |  |  |  |  |  |
| Female | 9 | 18.5 | 48.6 | (22.2-92.2) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 4 | 6.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 5 | 6.3 | 80.0 | (25.8-186.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 67 | 56.6 | 118.3 | (91.7-150.3) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.2 | 87.3 | (37.6-172.0) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 4 | 5.5 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 4 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.7 | 118.5 | (51.0-233.6) |  | Male | 7 | 3.9 | 181.6 | (72.8-374.3) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 11 | 11.1 | 99.3 | (49.5-177.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 12 | 16.1 | 74.4 | (38.4-130.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 31.3 | 63.9 | (39.0-98.6) |  | Male | 197 | 223.5 | 88.2 | (76.3-101.4) |
| Female | 21 | 33.9 | 61.9 | (38.3-94.6) |  | Female | 205 | 231.5 | 88.6 | (76.8-101.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

324

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 19.7 | 157.6 | (107.1-223.7) |  | Male | 10 | 12.3 | 81.5 | (39.0-149.9) |
| Female | 7 | 7.6 | 92.4 | (37.0-190.4) |  | Female | 6 | 10.1 | 59.4 | (21.7-129.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 7 | 3.3 | 210.8 | (84.5-434.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 0.7 | nc | (nc-nc) |  | Male | 12 | 11.0 | 109.2 | (56.3-190.7) |
| Female | 78 | 76.6 | 101.8 | (80.5-127.1) |  | Female | 9 | 10.2 | 87.9 | (40.1-166.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 8.6 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.2 | 118.9 | (38.3-277.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 21.0 | 133.3 | (88.6-192.7) |  |  |  |  |  |  |
| Female | 27 | 23.0 | 117.2 | (77.2-170.5) |  | Female | 9 | 6.9 | 130.4 | (59.5-247.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.0 | 139.1 | (55.7-286.6) |  | Male | 7 | 6.8 | 103.2 | (41.4-212.7) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 9 | 7.7 | 116.2 | (53.0-220.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 56 | 62.5 | 89.6 | (67.7-116.4) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.2 | 97.6 | (46.7-179.6) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 7 | 6.2 | 113.1 | (45.3-233.0) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.9 | 172.4 | (55.5-402.2) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 7.6 | 144.8 | (72.2-259.0) |  | Male | 6 | 4.6 | 131.7 | (48.1-286.7) |
| Female | 7 | 6.1 | 115.6 | (46.3-238.2) |  | Female | 12 | 14.0 | 85.7 | (44.2-149.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 6.5 | 154.5 | (74.0-284.1) |  |  |  |  |  |  |
| Female | 6 | 2.3 | 264.1 | (96.4-574.9) |  | Female | 18 | 16.8 | 107.1 | (63.4-169.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 34.6 | 121.3 | (87.4-164.0) |  | Male | 282 | 249.6 | 113.0 | (100.2-127.0) |
| Female | 48 | 37.9 | 126.5 | (93.3-167.8) |  | Female | 284 | 268.1 | 105.9 | (94.0-119.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

325

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 29.7 | 70.8 | (43.8-108.2) |  | Male | 30 | 18.5 | 162.2 | (109.4-231.6) |
| Female | 5 | 9.9 | 50.5 | (16.3-118.0) |  | Female | 31 | 14.0 | 221.7 | (150.6-314.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.5 | nc | (nc-nc) |  | Male | 5 | 5.9 | 84.9 | (27.4-198.2) |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 7 | 4.4 | 159.3 | (63.8-328.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 16 | 16.7 | 96.1 | (54.9-156.1) |
| Female | 134 | 108.5 | 123.5 | (103.5-146.3) |  | Female | 12 | 13.8 | 86.8 | (44.8-151.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 13.3 | 60.2 | (25.9-118.6) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 5 | 5.8 | 85.9 | (27.7-200.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 31.5 | 63.4 | (38.7-98.0) |  |  |  |  |  |  |
| Female | 25 | 29.8 | 83.8 | (54.2-123.8) |  | Female | 10 | 9.7 | 102.9 | (49.3-189.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 7.8 | nc | (nc-nc) |  | Male | 10 | 10.4 | 96.5 | (46.2-177.6) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 11 | 9.9 | 111.5 | (55.6-199.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 122 | 97.8 | 124.7 | (103.6-148.9) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 15.8 | 50.8 | (21.9-100.1) |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 8 | 8.6 | 92.8 | (40.0-182.9) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 11.8 | 101.4 | (52.3-177.1) |  | Male | 10 | 6.8 | 147.7 | (70.7-271.6) |
| Female | 12 | 8.4 | 142.7 | (73.6-249.2) |  | Female | 17 | 20.6 | 82.4 | (48.0-132.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 9.9 | 60.7 | (22.2-132.2) |  |  |  |  |  |  |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 17 | 24.1 | 70.6 | (41.1-113.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 52.5 | 32.4 | (18.8-51.8) |  | Male | 327 | 381.3 | 85.8 | (76.7-95.6) |
| Female | 33 | 52.0 | 63.4 | (43.6-89.0) |  | Female | 367 | 370.5 | 99.1 | (89.2-109.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

326

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.2 | 97.8 | (39.2-201.4) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 5 | 3.0 | 164.3 | (52.9-383.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 22 | 25.2 | 87.4 | (54.7-132.3) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 6.7 | 165.4 | (82.4-295.9) |  |  |  |  |  |  |
| Female | 6 | 7.7 | 78.4 | (28.6-170.6) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 5 | 2.8 | 177.5 | (57.2-414.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 21 | 24.7 | 85.1 | (52.7-130.1) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 13.5 | 36.9 | (11.9-86.2) |  | Male | 71 | 88.2 | 80.5 | (62.9-101.6) |
| Female | 12 | 14.7 | 81.4 | (42.0-142.3) |  | Female | 71 | 90.4 | 78.6 | (61.3-99.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

327

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 5.2 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 11 | 21.0 | 52.4 | (26.1-93.9) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 10 | 15.9 | 63.0 | (30.2-115.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

328

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.1 | 156.4 | (67.3-308.1) |  | Male | 6 | 3.1 | 191.3 | (69.8-416.3) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 6 | 2.3 | 264.3 | (96.5-575.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 22 | 17.3 | 127.1 | (79.6-192.5) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 4.8 | 145.1 | (58.2-299.1) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 14.8 | 162.1 | (103.8-241.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 5 | 3.4 | 148.8 | (48.0-347.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 8 | 3.9 | 207.3 | (89.3-408.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 9.0 | nc | (nc-nc) |  | Male | 67 | 62.8 | 106.6 | (82.6-135.4) |
| Female | 10 | 8.1 | 123.7 | (59.2-227.5) |  | Female | 73 | 59.0 | 123.6 | (96.9-155.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

329

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 9.0 | 210.3 | (126.6-328.4) |  | Male | 5 | 6.1 | 82.3 | (26.5-192.1) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.4 | 92.6 | (29.8-216.0) |
| Female | 31 | 30.3 | 102.3 | (69.5-145.1) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 9.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 9.4 | 63.9 | (23.3-139.1) |  | Female | 5 | 2.8 | 181.0 | (58.3-422.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 20 | 30.9 | 64.7 | (39.5-100.0) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.1 | 137.1 | (54.9-282.6) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 11 | 4.8 | 229.1 | (114.2-409.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 5 | 7.0 | 71.6 | (23.1-167.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 16.1 | 123.9 | (75.6-191.3) |  | Male | 114 | 121.7 | 93.7 | (77.3-112.5) |
| Female | 12 | 16.2 | 74.3 | (38.3-129.7) |  | Female | 109 | 107.8 | 101.1 | (83.0-121.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

330

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 8.9 | 78.9 | (31.6-162.6) |  | Male | 10 | 5.5 | 183.4 | (87.8-337.3) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.6 | 317.9 | (102.4-741.8) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.9 | 102.5 | (33.0-239.2) |
| Female | 34 | 31.5 | 108.1 | (74.8-151.0) |  | Female | 8 | 4.0 | 200.4 | (86.3-394.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.8 | 131.6 | (42.4-307.1) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.2 | 75.8 | (30.4-156.1) |  |  |  |  |  |  |
| Female | 16 | 8.6 | 186.7 | (106.7-303.2) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 2.3 | 263.3 | (96.2-573.2) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 27 | 28.4 | 95.0 | (62.6-138.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 4 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.4 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 11 | 5.6 | 196.9 | (98.2-352.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 7.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 15.6 | 96.4 | (53.9-159.0) |  | Male | 111 | 111.8 | 99.3 | (81.7-119.6) |
| Female | 18 | 15.1 | 119.5 | (70.8-188.8) |  | Female | 121 | 106.5 | 113.6 | (94.2-135.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

331

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 2.9 | nc | (nc-nc) |
| Female | 13 | 16.7 | 77.7 | (41.4-132.9) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.6 | 108.1 | (39.5-235.3) |  |  |  |  |  |  |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 4 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 11 | 16.9 | 65.0 | (32.4-116.3) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 3.9 | 154.5 | (56.4-336.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 9.5 | 94.5 | (43.1-179.3) |  | Male | 50 | 67.3 | 74.3 | (55.2-98.0) |
| Female | 15 | 8.5 | 177.3 | (99.2-292.5) |  | Female | 61 | 59.4 | 102.6 | (78.5-131.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

332

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 22 | 17.4 | 126.5 | (79.3-191.6) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 17 | 18.0 | 94.4 | (55.0-151.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 2.8 | 180.8 | (58.3-422.0) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 8.3 | nc | (nc-nc) |  | Male | 55 | 65.0 | 84.6 | (63.7-110.1) |
| Female | 5 | 7.2 | 69.6 | (22.4-162.4) |  | Female | 50 | 55.1 | 90.7 | (67.3-119.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

333

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 30.4 | 111.8 | (77.4-156.3) |  | Male | 14 | 19.6 | 71.5 | (39.0-119.9) |
| Female | 6 | 11.7 | 51.5 | (18.8-112.0) |  | Female | 12 | 16.0 | 75.2 | (38.8-131.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.0 | 116.7 | (46.7-240.4) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 15 | 17.5 | 85.9 | (48.1-141.7) |
| Female | 102 | 122.7 | 83.1 | (67.8-100.9) |  | Female | 8 | 15.9 | 50.3 | (21.7-99.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 14.1 | 127.7 | (75.6-201.8) |
| Female | 10 | 4.1 | 242.2 | (116.0-445.5) |  | Female | 9 | 6.6 | 136.2 | (62.2-258.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 41 | 32.4 | 126.5 | (90.8-171.7) |  |  |  |  |  |  |
| Female | 41 | 35.0 | 117.3 | (84.1-159.1) |  | Female | 9 | 11.0 | 81.8 | (37.3-155.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.1 | 135.5 | (67.5-242.5) |  | Male | 12 | 10.7 | 112.2 | (57.9-196.0) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 9 | 11.6 | 77.4 | (35.3-146.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 82 | 103.8 | 79.0 | (62.9-98.1) |
| Female | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 16.6 | 84.2 | (46.0-141.2) |  | Male | 4 | 7.1 | nc | (nc-nc) |
| Female | 9 | 10.0 | 90.4 | (41.3-171.7) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 5 | 4.4 | 113.4 | (36.6-264.7) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 12.3 | 64.9 | (28.0-128.0) |  | Male | 9 | 7.6 | 118.9 | (54.2-225.7) |
| Female | 10 | 9.4 | 106.8 | (51.1-196.4) |  | Female | 21 | 22.6 | 93.1 | (57.6-142.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 10.6 | 122.5 | (65.1-209.4) |  |  |  |  |  |  |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 27 | 27.6 | 98.0 | (64.6-142.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 48 | 54.8 | 87.7 | (64.6-116.2) |  | Male | 371 | 401.6 | 92.4 | (83.2-102.3) |
| Female | 85 | 60.6 | 140.3 | (112.1-173.5) |  | Female | 411 | 423.2 | 97.1 | (88.0-107.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

334

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 7 | 7.7 | 91.3 | (36.6-188.0) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 11 | 7.1 | 155.4 | (77.5-278.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 3.6 | 169.0 | (61.7-367.9) |  | Male | 30 | 25.6 | 117.2 | (79.1-167.3) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 24 | 25.9 | 92.7 | (59.4-138.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

335

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 2.4 | 254.5 | (92.9-554.0) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 20 | 14.5 | 137.7 | (84.0-212.6) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 11 | 10.7 | 103.1 | (51.4-184.5) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 1.5 | 403.5 | (147.4-878.4) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 48 | 34.9 | 137.7 | (101.5-182.5) |
| Female | 7 | 6.5 | 107.2 | (42.9-220.9) |  | Female | 51 | 48.2 | 105.8 | (78.8-139.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

336

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 17.4 | 68.9 | (35.6-120.4) |  | Male | 13 | 11.7 | 111.3 | (59.2-190.3) |
| Female | 7 | 6.6 | 105.3 | (42.2-217.0) |  | Female | 5 | 9.6 | 52.0 | (16.8-121.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.6 | 137.6 | (44.4-321.2) |  | Male | 7 | 3.6 | 192.2 | (77.0-396.1) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 10 | 10.5 | 95.3 | (45.6-175.2) |
| Female | 84 | 73.8 | 113.8 | (90.8-140.9) |  | Female | 7 | 9.3 | 75.3 | (30.2-155.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.5 | 82.3 | (33.0-169.6) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 19.8 | 85.8 | (50.0-137.4) |  |  |  |  |  |  |
| Female | 25 | 20.8 | 120.2 | (77.7-177.4) |  | Female | 5 | 6.6 | 75.9 | (24.5-177.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 5 | 6.1 | 81.3 | (26.2-189.8) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 6 | 6.8 | 88.0 | (32.1-191.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 54 | 56.6 | 95.4 | (71.7-124.5) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 10.0 | 79.9 | (34.4-157.5) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 2 | 5.7 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.3 | 123.9 | (56.6-235.3) |  | Male | 8 | 4.9 | 163.6 | (70.4-322.3) |
| Female | 9 | 5.6 | 159.7 | (72.9-303.2) |  | Female | 12 | 14.2 | 84.3 | (43.5-147.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.2 | 80.5 | (25.9-187.8) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 19 | 16.2 | 117.4 | (70.7-183.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 30.8 | 74.6 | (47.3-112.0) |  | Male | 215 | 232.1 | 92.6 | (80.7-105.9) |
| Female | 33 | 32.7 | 100.9 | (69.5-141.8) |  | Female | 241 | 249.4 | 96.6 | (84.8-109.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

337

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 44 | 41.8 | 105.2 | (76.5-141.3) |  | Male | 24 | 26.9 | 89.1 | (57.1-132.6) |
| Female | 14 | 15.0 | 93.1 | (50.8-156.2) |  | Female | 20 | 21.4 | 93.3 | (57.0-144.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 8.3 | 60.5 | (19.5-141.3) |  | Male | 9 | 8.4 | 107.1 | (48.9-203.3) |
| Female | 7 | 6.8 | 102.6 | (41.1-211.4) |  | Female | 0 | 6.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 21 | 24.2 | 86.7 | (53.6-132.5) |
| Female | 183 | 165.1 | 110.8 | (95.3-128.1) |  | Female | 19 | 21.0 | 90.3 | (54.4-141.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 19.4 | 66.9 | (35.6-114.4) |
| Female | 8 | 5.5 | 146.1 | (62.9-287.9) |  | Female | 9 | 8.9 | 101.7 | (46.4-193.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 47 | 45.3 | 103.9 | (76.3-138.1) |  |  |  |  |  |  |
| Female | 52 | 45.3 | 114.7 | (85.7-150.4) |  | Female | 19 | 14.8 | 128.1 | (77.1-200.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 11.1 | 135.6 | (75.9-223.7) |  | Male | 9 | 14.7 | 61.1 | (27.9-115.9) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 13 | 15.2 | 85.8 | (45.6-146.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.5 | 173.7 | (63.4-378.0) |  | Male | 124 | 140.7 | 88.2 | (73.3-105.1) |
| Female | 1 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 22.8 | 74.5 | (43.4-119.2) |  | Male | 15 | 9.8 | 152.9 | (85.5-252.1) |
| Female | 10 | 13.1 | 76.1 | (36.4-139.9) |  | Female | 6 | 5.9 | 102.4 | (37.4-223.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.4 | nc | (nc-nc) |  | Male | 5 | 6.3 | 80.0 | (25.8-186.6) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 17.1 | 128.9 | (80.8-195.2) |  | Male | 6 | 10.5 | 56.9 | (20.8-124.0) |
| Female | 11 | 12.5 | 88.3 | (44.0-158.1) |  | Female | 19 | 30.7 | 61.8 | (37.2-96.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 14.5 | 82.6 | (42.6-144.3) |  |  |  |  |  |  |
| Female | 2 | 4.8 | nc | (nc-nc) |  | Female | 33 | 38.0 | 86.9 | (59.8-122.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 79 | 74.3 | 106.3 | (84.2-132.5) |  | Male | 529 | 550.9 | 96.0 | (88.0-104.6) |
| Female | 81 | 78.8 | 102.8 | (81.6-127.8) |  | Female | 547 | 562.9 | 97.2 | (89.2-105.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

338

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 19.3 | 62.3 | (32.1-108.8) |  | Male | 19 | 13.8 | 137.6 | (82.8-214.9) |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 12 | 10.9 | 109.9 | (56.7-191.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 7 | 4.4 | 160.7 | (64.4-331.2) |
| Female | 6 | 3.5 | 171.2 | (62.5-372.6) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 13 | 12.4 | 104.5 | (55.6-178.7) |
| Female | 88 | 89.9 | 97.9 | (78.5-120.6) |  | Female | 8 | 9.9 | 80.7 | (34.8-159.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 11.4 | 87.8 | (42.0-161.5) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.4 | (36.5-264.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 22.9 | 91.5 | (56.6-139.9) |  |  |  |  |  |  |
| Female | 21 | 20.2 | 104.1 | (64.4-159.2) |  | Female | 6 | 7.7 | 78.1 | (28.5-170.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.9 | nc | (nc-nc) |  | Male | 8 | 7.4 | 108.8 | (46.8-214.4) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 7 | 6.4 | 110.2 | (44.1-227.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 76 | 81.8 | 92.9 | (73.2-116.3) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 13.1 | 84.2 | (42.0-150.7) |  | Male | 6 | 4.9 | 123.2 | (45.0-268.2) |
| Female | 3 | 6.6 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 3.6 | 166.9 | (61.0-363.4) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 8.4 | 154.9 | (82.4-264.9) |  | Male | 9 | 6.2 | 144.6 | (66.0-274.5) |
| Female | 11 | 5.7 | 193.1 | (96.3-345.6) |  | Female | 15 | 17.7 | 84.8 | (47.4-139.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 8.2 | 61.3 | (19.8-143.1) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 35 | 20.8 | 168.4 | (117.3-234.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 37.1 | 97.0 | (68.0-134.3) |  | Male | 283 | 290.7 | 97.4 | (86.3-109.4) |
| Female | 28 | 35.9 | 78.0 | (51.8-112.8) |  | Female | 275 | 280.7 | 98.0 | (86.7-110.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

339

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 6 | 1.2 | 503.9 | (184.0-1096.8) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 11 | 7.6 | 145.5 | (72.5-260.4) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 7.0 | 114.3 | (49.2-225.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 25 | 25.1 | 99.6 | (64.4-147.0) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 17 | 23.9 | 71.2 | (41.4-114.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

340

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.5 | 93.7 | (37.5-193.1) |  | Male | 6 | 5.1 | 118.0 | (43.1-256.9) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 6 | 3.6 | 166.9 | (61.0-363.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.6 | 130.3 | (47.6-283.7) |
| Female | 43 | 29.2 | 147.3 | (106.6-198.4) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 1.4 | 347.4 | (111.9-810.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 8.7 | 91.9 | (39.6-181.1) |  |  |  |  |  |  |
| Female | 7 | 6.5 | 106.9 | (42.8-220.3) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 26 | 26.8 | 97.1 | (63.4-142.3) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 7 | 5.9 | 118.9 | (47.6-244.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 8 | 6.9 | 116.3 | (50.1-229.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 13.2 | 68.0 | (31.0-129.1) |  | Male | 100 | 103.5 | 96.6 | (78.6-117.5) |
| Female | 14 | 11.2 | 125.4 | (68.5-210.4) |  | Female | 111 | 90.9 | 122.1 | (100.4-147.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

341

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 15.3 | 98.2 | (54.9-161.9) |  | Male | 11 | 9.3 | 118.1 | (58.9-211.3) |
| Female | 2 | 4.8 | nc | (nc-nc) |  | Female | 10 | 6.5 | 154.4 | (73.9-284.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.3 | 108.4 | (49.5-205.8) |
| Female | 50 | 52.1 | 95.9 | (71.2-126.4) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.6 | 91.4 | (33.4-198.8) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 15.9 | 75.5 | (39.0-132.0) |  |  |  |  |  |  |
| Female | 13 | 14.4 | 90.4 | (48.1-154.6) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 8 | 4.8 | 166.8 | (71.8-328.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 55 | 48.9 | 112.5 | (84.7-146.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.7 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.9 | 153.2 | (69.9-290.9) |  | Male | 6 | 3.2 | 189.1 | (69.1-411.6) |
| Female | 10 | 3.9 | 258.2 | (123.6-474.8) |  | Female | 6 | 8.9 | 67.7 | (24.7-147.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 7 | 12.0 | 58.2 | (23.3-119.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 27.2 | 80.9 | (50.7-122.5) |  | Male | 195 | 191.8 | 101.7 | (87.9-117.0) |
| Female | 20 | 25.0 | 79.9 | (48.8-123.3) |  | Female | 153 | 176.6 | 86.6 | (73.5-101.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

342

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 23.4 | 128.2 | (86.4-183.0) |  | Male | 16 | 14.2 | 112.4 | (64.2-182.5) |
| Female | 10 | 7.5 | 132.9 | (63.6-244.4) |  | Female | 9 | 9.9 | 90.5 | (41.3-171.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 5 | 4.6 | 108.6 | (35.0-253.3) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 6 | 3.4 | 175.6 | (64.1-382.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 15 | 12.6 | 119.2 | (66.6-196.6) |
| Female | 74 | 80.9 | 91.5 | (71.8-114.8) |  | Female | 16 | 10.4 | 154.3 | (88.1-250.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.9 | 70.8 | (28.4-145.9) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 6 | 4.4 | 135.9 | (49.6-295.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 23.7 | 84.3 | (51.5-130.3) |  |  |  |  |  |  |
| Female | 17 | 22.0 | 77.2 | (45.0-123.7) |  | Female | 4 | 7.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 6.1 | 148.1 | (67.6-281.2) |  | Male | 11 | 8.1 | 135.7 | (67.6-242.8) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 8 | 7.5 | 106.6 | (45.9-210.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 91 | 77.8 | 116.9 | (94.2-143.6) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 11.9 | 84.0 | (40.2-154.5) |  | Male | 6 | 5.3 | 112.5 | (41.1-245.0) |
| Female | 5 | 6.5 | 77.1 | (24.8-179.8) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 8.7 | 92.0 | (39.6-181.3) |  | Male | 7 | 4.9 | 143.5 | (57.5-295.7) |
| Female | 3 | 5.8 | nc | (nc-nc) |  | Female | 15 | 13.4 | 112.1 | (62.7-184.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.6 | 65.8 | (21.2-153.6) |  |  |  |  |  |  |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 11 | 19.2 | 57.2 | (28.5-102.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 41.9 | 81.2 | (56.2-113.5) |  | Male | 299 | 295.2 | 101.3 | (90.1-113.5) |
| Female | 38 | 40.4 | 94.2 | (66.6-129.2) |  | Female | 249 | 274.8 | 90.6 | (79.7-102.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

343

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 20.0 | 99.8 | (60.9-154.1) |  | Male | 24 | 12.0 | 200.6 | (128.5-298.4) |
| Female | 5 | 7.5 | 66.7 | (21.5-155.6) |  | Female | 22 | 9.1 | 242.8 | (152.1-367.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 5 | 3.8 | 131.0 | (42.2-305.8) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 5 | 3.2 | 154.5 | (49.8-360.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 9 | 10.8 | 83.0 | (37.9-157.6) |
| Female | 95 | 71.4 | 133.0 | (107.6-162.6) |  | Female | 4 | 9.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.3 | 84.6 | (33.9-174.3) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 6 | 4.0 | 148.8 | (54.3-323.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 21.3 | 131.7 | (87.5-190.4) |  |  |  |  |  |  |
| Female | 27 | 22.9 | 117.7 | (77.6-171.3) |  | Female | 9 | 6.5 | 139.2 | (63.5-264.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 11 | 6.9 | 160.5 | (80.0-287.3) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 4 | 7.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.1 | nc | (nc-nc) |  | Male | 64 | 58.4 | 109.5 | (84.4-139.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.7 | 102.7 | (49.2-188.9) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 6 | 5.8 | 103.5 | (37.8-225.2) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.7 | 117.3 | (53.5-222.7) |  | Male | 5 | 4.1 | 121.8 | (39.3-284.2) |
| Female | 10 | 5.8 | 171.9 | (82.3-316.2) |  | Female | 19 | 11.3 | 167.7 | (100.9-261.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 19 | 15.6 | 121.5 | (73.1-189.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 33.7 | 74.2 | (48.0-109.5) |  | Male | 260 | 242.7 | 107.1 | (94.5-121.0) |
| Female | 37 | 36.2 | 102.1 | (71.9-140.8) |  | Female | 296 | 252.9 | 117.0 | (104.1-131.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

344

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 57.7 | 91.8 | (68.7-120.1) |  | Male | 40 | 37.5 | 106.7 | (76.2-145.3) |
| Female | 39 | 24.3 | 160.6 | (114.2-219.6) |  | Female | 45 | 33.5 | 134.5 | (98.1-180.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 11.2 | 89.1 | (42.6-163.8) |  | Male | 16 | 11.8 | 135.7 | (77.5-220.4) |
| Female | 10 | 10.3 | 96.9 | (46.4-178.3) |  | Female | 7 | 11.0 | 63.9 | (25.6-131.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 45 | 33.4 | 134.6 | (98.2-180.1) |
| Female | 275 | 264.7 | 103.9 | (92.0-116.9) |  | Female | 27 | 33.8 | 79.9 | (52.6-116.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 27.1 | 121.7 | (83.7-170.9) |
| Female | 5 | 8.8 | 56.8 | (18.3-132.6) |  | Female | 20 | 14.2 | 140.5 | (85.8-217.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 66 | 62.9 | 104.9 | (81.1-133.4) |  |  |  |  |  |  |
| Female | 77 | 73.2 | 105.2 | (83.1-131.5) |  | Female | 26 | 23.5 | 110.4 | (72.1-161.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 15.4 | 91.1 | (49.8-152.9) |  | Male | 22 | 20.3 | 108.2 | (67.8-163.8) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 21 | 24.3 | 86.5 | (53.5-132.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 4.4 | 137.6 | (50.2-299.5) |  | Male | 179 | 194.0 | 92.3 | (79.3-106.8) |
| Female | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 31.9 | 109.7 | (76.4-152.6) |  | Male | 13 | 13.6 | 95.4 | (50.8-163.2) |
| Female | 27 | 21.0 | 128.4 | (84.6-186.8) |  | Female | 5 | 9.4 | 53.4 | (17.2-124.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 9.0 | 189.4 | (110.3-303.2) |  | Male | 8 | 7.9 | 100.6 | (43.3-198.3) |
| Female | 3 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 23.2 | 81.8 | (49.2-127.7) |  | Male | 15 | 14.6 | 102.5 | (57.3-169.0) |
| Female | 13 | 19.3 | 67.4 | (35.9-115.3) |  | Female | 54 | 47.1 | 114.7 | (86.1-149.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 20.4 | 93.3 | (56.2-145.7) |  |  |  |  |  |  |
| Female | 9 | 7.7 | 116.4 | (53.1-221.0) |  | Female | 64 | 60.5 | 105.8 | (81.4-135.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 112 | 103.5 | 108.2 | (89.1-130.3) |  | Male | 796 | 761.6 | 104.5 | (97.4-112.0) |
| Female | 155 | 128.0 | 121.1 | (102.8-141.7) |  | Female | 955 | 898.6 | 106.3 | (99.6-113.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

345

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 5 | 6.8 | 73.7 | (23.8-172.0) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 7.2 | 83.1 | (30.4-180.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 25 | 25.6 | 97.6 | (63.1-144.0) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 15 | 22.0 | 68.1 | (38.1-112.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

346

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 14.4 | 208.6 | (140.7-297.9) |  | Male | 7 | 9.6 | 73.1 | (29.3-150.6) |
| Female | 5 | 4.6 | 107.9 | (34.8-251.8) |  | Female | 12 | 7.3 | 163.9 | (84.6-286.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 8.6 | nc | (nc-nc) |
| Female | 54 | 57.3 | 94.3 | (70.8-123.1) |  | Female | 5 | 6.9 | 73.0 | (23.5-170.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.1 | 70.0 | (22.6-163.3) |
| Female | 5 | 2.1 | 243.4 | (78.5-568.1) |  | Female | 7 | 2.9 | 238.3 | (95.5-491.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 16.0 | 99.8 | (57.0-162.1) |  |  |  |  |  |  |
| Female | 20 | 14.4 | 139.3 | (85.1-215.2) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.0 | 151.6 | (55.3-329.9) |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.6 | 107.8 | (34.7-251.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 51 | 51.4 | 99.2 | (73.9-130.5) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 8.4 | 225.7 | (135.8-352.5) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.3 | 217.1 | (70.0-506.7) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.0 | 132.8 | (57.2-261.7) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 10 | 11.4 | 87.9 | (42.1-161.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 12 | 13.2 | 91.2 | (47.1-159.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 26.0 | 134.8 | (93.9-187.5) |  | Male | 213 | 196.5 | 108.4 | (94.3-124.0) |
| Female | 37 | 25.2 | 147.0 | (103.5-202.6) |  | Female | 196 | 187.9 | 104.3 | (90.2-120.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

347

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 21.6 | 69.3 | (38.8-114.3) |  | Male | 22 | 13.0 | 168.8 | (105.7-255.6) |
| Female | 9 | 7.3 | 123.5 | (56.4-234.5) |  | Female | 9 | 9.3 | 97.2 | (44.3-184.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 7 | 2.8 | 246.2 | (98.6-507.2) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 8 | 11.6 | 69.0 | (29.7-136.0) |
| Female | 83 | 74.9 | 110.8 | (88.2-137.3) |  | Female | 11 | 9.7 | 113.4 | (56.5-202.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 9.1 | 66.2 | (24.2-144.1) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 22.2 | 80.9 | (47.9-127.9) |  |  |  |  |  |  |
| Female | 15 | 21.9 | 68.5 | (38.3-113.0) |  | Female | 4 | 6.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 4 | 7.5 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 13 | 7.4 | 175.5 | (93.4-300.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 50 | 68.7 | 72.8 | (54.0-95.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.7 | 93.2 | (44.6-171.4) |  | Male | 5 | 4.9 | 101.5 | (32.7-236.9) |
| Female | 4 | 6.0 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 8.1 | nc | (nc-nc) |  | Male | 5 | 4.3 | 115.1 | (37.1-268.6) |
| Female | 8 | 5.6 | 142.7 | (61.4-281.2) |  | Female | 10 | 11.8 | 84.4 | (40.4-155.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 7.0 | 114.9 | (49.5-226.4) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 12 | 17.2 | 70.0 | (36.1-122.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 38.2 | 68.0 | (44.4-99.7) |  | Male | 211 | 268.4 | 78.6 | (68.4-90.0) |
| Female | 24 | 37.1 | 64.7 | (41.5-96.3) |  | Female | 240 | 257.1 | 93.3 | (81.9-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

348

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 18 | 14.0 | 128.5 | (76.1-203.1) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 3.8 | 133.2 | (42.9-310.9) |  | Female | 5 | 1.3 | 398.3 | (128.4-929.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 12.8 | 62.6 | (26.9-123.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  | Male | 32 | 45.7 | 70.0 | (47.9-98.8) |
| Female | 2 | 6.3 | nc | (nc-nc) |  | Female | 45 | 46.5 | 96.7 | (70.5-129.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

349

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 11.9 | 67.3 | (29.0-132.7) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 6.0 | 100.7 | (36.8-219.2) |
| Female | 26 | 35.0 | 74.3 | (48.5-108.8) |  | Female | 5 | 5.2 | 96.2 | (31.0-224.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 11.6 | 60.5 | (24.2-124.7) |  |  |  |  |  |  |
| Female | 8 | 12.0 | 66.7 | (28.7-131.5) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 36 | 33.1 | 108.9 | (76.3-150.8) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 5 | 5.5 | 91.7 | (29.6-214.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 3 | 8.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 19.9 | 45.3 | (20.7-86.0) |  | Male | 99 | 136.0 | 72.8 | (59.2-88.6) |
| Female | 15 | 19.9 | 75.4 | (42.2-124.3) |  | Female | 93 | 131.1 | 71.0 | (57.3-86.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

350

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 21.8 | 123.9 | (81.7-180.3) |  | Male | 11 | 14.4 | 76.3 | (38.1-136.6) |
| Female | 8 | 8.1 | 98.4 | (42.4-193.9) |  | Female | 15 | 12.1 | 124.3 | (69.5-205.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 8 | 3.7 | 215.3 | (92.7-424.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 8 | 13.1 | 61.3 | (26.4-120.7) |
| Female | 110 | 96.5 | 114.0 | (93.7-137.4) |  | Female | 16 | 11.6 | 138.1 | (78.9-224.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 10.8 | 83.5 | (38.1-158.4) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 6 | 5.0 | 121.1 | (44.2-263.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 24.5 | 98.0 | (62.8-145.9) |  |  |  |  |  |  |
| Female | 27 | 24.8 | 108.7 | (71.6-158.1) |  | Female | 8 | 8.4 | 95.0 | (40.9-187.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.9 | 84.9 | (27.4-198.2) |  | Male | 6 | 7.8 | 77.0 | (28.1-167.7) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 9 | 8.1 | 111.3 | (50.8-211.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 62 | 74.4 | 83.3 | (63.9-106.8) |
| Female | 3 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 12.6 | 142.5 | (84.4-225.2) |  | Male | 5 | 5.2 | 95.7 | (30.8-223.3) |
| Female | 8 | 7.5 | 106.8 | (46.0-210.4) |  | Female | 5 | 3.2 | 157.4 | (50.7-367.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 0 | 3.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 9.2 | 141.1 | (75.0-241.2) |  | Male | 8 | 5.9 | 135.0 | (58.1-266.0) |
| Female | 5 | 6.8 | 73.5 | (23.7-171.5) |  | Female | 14 | 18.1 | 77.4 | (42.3-129.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 23 | 21.7 | 106.1 | (67.2-159.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 38.7 | 131.6 | (98.0-173.1) |  | Male | 291 | 293.3 | 99.2 | (88.1-111.3) |
| Female | 48 | 43.7 | 109.8 | (80.9-145.5) |  | Female | 347 | 317.8 | 109.2 | (98.0-121.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

351

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 11.6 | 103.4 | (53.4-180.6) |  | Male | 1 | 7.8 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 3 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 6.9 | nc | (nc-nc) |
| Female | 32 | 45.3 | 70.7 | (48.3-99.8) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 5.9 | 101.3 | (37.0-220.4) |
| Female | 4 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 13.0 | 61.5 | (26.5-121.3) |  |  |  |  |  |  |
| Female | 15 | 11.0 | 136.3 | (76.2-224.8) |  | Female | 6 | 3.9 | 153.2 | (55.9-333.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 8 | 4.2 | 190.1 | (81.9-374.6) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.5 | 142.5 | (45.9-332.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 32 | 42.1 | 76.1 | (52.0-107.4) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.8 | 73.6 | (23.7-171.7) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 5 | 3.5 | 144.1 | (46.4-336.3) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.8 | 146.6 | (58.7-302.0) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 8 | 8.3 | 95.9 | (41.3-188.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 10 | 10.3 | 97.3 | (46.6-179.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 21.4 | 60.7 | (32.3-103.9) |  | Male | 118 | 159.7 | 73.9 | (61.1-88.5) |
| Female | 23 | 20.4 | 112.6 | (71.3-168.9) |  | Female | 139 | 145.8 | 95.3 | (80.1-112.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

352

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 23.6 | 101.5 | (65.0-151.0) |  | Male | 19 | 15.0 | 126.4 | (76.1-197.4) |
| Female | 5 | 9.2 | 54.1 | (17.4-126.2) |  | Female | 15 | 12.3 | 121.9 | (68.2-201.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 5 | 4.8 | 104.2 | (33.6-243.2) |
| Female | 11 | 4.0 | 276.8 | (138.0-495.4) |  | Female | 6 | 4.1 | 146.8 | (53.6-319.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 19 | 13.5 | 140.7 | (84.7-219.8) |
| Female | 115 | 98.8 | 116.4 | (96.1-139.7) |  | Female | 13 | 12.6 | 103.4 | (55.0-176.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 10.6 | nc | (nc-nc) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 25.7 | 93.3 | (59.7-138.8) |  |  |  |  |  |  |
| Female | 27 | 28.2 | 95.6 | (63.0-139.1) |  | Female | 9 | 8.7 | 103.6 | (47.3-196.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  | Male | 5 | 8.2 | 61.0 | (19.7-142.4) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 8 | 9.3 | 85.6 | (36.9-168.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 81 | 74.6 | 108.5 | (86.2-134.9) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 12.8 | 62.6 | (27.0-123.4) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 9 | 7.9 | 114.3 | (52.2-217.1) |  | Female | 5 | 3.7 | 136.5 | (44.0-318.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 9.4 | 170.4 | (97.3-276.8) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 5 | 7.5 | 66.4 | (21.4-154.9) |  | Female | 22 | 17.2 | 127.6 | (79.9-193.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 24 | 21.5 | 111.8 | (71.6-166.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 41.9 | 69.2 | (46.3-99.4) |  | Male | 285 | 302.8 | 94.1 | (83.5-105.7) |
| Female | 41 | 47.5 | 86.4 | (62.0-117.1) |  | Female | 351 | 336.0 | 104.5 | (93.8-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

353

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 11 | 18.5 | 59.6 | (29.7-106.6) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 16 | 14.3 | 111.8 | (63.9-181.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

354

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 22.7 | 101.2 | (64.1-151.8) |  | Male | 28 | 14.7 | 190.2 | (126.3-274.8) |
| Female | 7 | 7.0 | 99.4 | (39.8-204.9) |  | Female | 18 | 10.2 | 176.3 | (104.4-278.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 8 | 3.2 | 250.7 | (107.9-494.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 4 | 12.9 | nc | (nc-nc) |
| Female | 88 | 79.2 | 111.0 | (89.1-136.8) |  | Female | 11 | 9.9 | 110.8 | (55.2-198.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 10.7 | 93.0 | (44.5-171.1) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 24.1 | 111.9 | (73.7-162.8) |  |  |  |  |  |  |
| Female | 28 | 20.9 | 133.8 | (88.9-193.4) |  | Female | 12 | 7.0 | 170.7 | (88.1-298.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.2 | 96.6 | (35.3-210.2) |  | Male | 14 | 8.1 | 173.0 | (94.5-290.3) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 7 | 7.0 | 100.5 | (40.2-207.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 74 | 81.5 | 90.8 | (71.3-114.0) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 12.7 | 196.7 | (127.2-290.3) |  | Male | 5 | 5.4 | 93.4 | (30.1-218.0) |
| Female | 13 | 6.3 | 206.2 | (109.7-352.6) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 8.9 | 67.7 | (24.7-147.4) |  | Male | 9 | 5.6 | 161.3 | (73.6-306.2) |
| Female | 6 | 5.7 | 105.7 | (38.6-230.1) |  | Female | 15 | 14.9 | 100.8 | (56.4-166.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 8.1 | 98.7 | (42.5-194.4) |  |  |  |  |  |  |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 19 | 18.2 | 104.2 | (62.7-162.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 55 | 42.0 | 130.9 | (98.6-170.4) |  | Male | 331 | 304.0 | 108.9 | (97.5-121.3) |
| Female | 49 | 38.3 | 127.8 | (94.5-169.0) |  | Female | 321 | 267.4 | 120.0 | (107.3-133.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

355

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 49 | 40.7 | 120.3 | (89.0-159.1) |  | Male | 31 | 26.6 | 116.7 | (79.2-165.6) |
| Female | 23 | 15.8 | 145.2 | (92.0-217.8) |  | Female | 21 | 22.0 | 95.5 | (59.1-145.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.0 | nc | (nc-nc) |  | Male | 9 | 8.2 | 109.5 | (50.0-208.0) |
| Female | 11 | 6.7 | 163.7 | (81.6-292.9) |  | Female | 7 | 7.1 | 99.0 | (39.7-203.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 32 | 23.7 | 135.1 | (92.4-190.7) |
| Female | 208 | 167.5 | 124.2 | (107.9-142.3) |  | Female | 28 | 21.8 | 128.3 | (85.3-185.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 18.8 | 100.8 | (60.7-157.4) |
| Female | 9 | 5.7 | 156.7 | (71.5-297.6) |  | Female | 10 | 9.1 | 109.9 | (52.6-202.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 60 | 44.4 | 135.1 | (103.1-173.9) |  |  |  |  |  |  |
| Female | 51 | 48.1 | 106.1 | (79.0-139.4) |  | Female | 16 | 15.1 | 105.9 | (60.5-172.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 10.6 | 112.8 | (58.2-197.0) |  | Male | 15 | 14.3 | 105.0 | (58.7-173.2) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 21 | 16.0 | 131.2 | (81.2-200.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 125 | 133.4 | 93.7 | (78.0-111.6) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 22.3 | 120.9 | (79.7-175.9) |  | Male | 11 | 9.6 | 114.4 | (57.1-204.8) |
| Female | 15 | 13.5 | 111.3 | (62.3-183.7) |  | Female | 6 | 6.2 | 96.7 | (35.3-210.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  | Male | 9 | 6.5 | 137.8 | (62.9-261.6) |
| Female | 5 | 2.0 | 250.3 | (80.7-584.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 16.5 | 121.5 | (74.2-187.7) |  | Male | 12 | 10.6 | 113.4 | (58.5-198.0) |
| Female | 15 | 12.8 | 117.0 | (65.4-192.9) |  | Female | 33 | 31.1 | 106.2 | (73.1-149.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 14.0 | 121.5 | (70.7-194.5) |  |  |  |  |  |  |
| Female | 1 | 4.9 | nc | (nc-nc) |  | Female | 40 | 37.9 | 105.7 | (75.5-143.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 98 | 72.1 | 136.0 | (110.4-165.7) |  | Male | 621 | 533.7 | 116.3 | (107.4-125.9) |
| Female | 81 | 81.4 | 99.5 | (79.0-123.7) |  | Female | 675 | 578.1 | 116.8 | (108.1-125.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

356

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 181 | 152.2 | 118.9 | (102.2-137.6) |  | Male | 65 | 100.7 | 64.6 | (49.8-82.3) |
| Female | 62 | 61.8 | 100.4 | (77.0-128.7) |  | Female | 56 | 90.8 | 61.7 | (46.6-80.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 30 | 32.7 | 91.6 | (61.8-130.8) |  | Male | 25 | 30.8 | 81.3 | (52.6-120.0) |
| Female | 24 | 28.9 | 82.9 | (53.1-123.4) |  | Female | 25 | 27.6 | 90.7 | (58.7-133.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  | Male | 103 | 91.1 | 113.1 | (92.3-137.1) |
| Female | 590 | 667.2 | 88.4 | (81.4-95.9) |  | Female | 80 | 86.5 | 92.4 | (73.3-115.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 67 | 72.3 | 92.7 | (71.8-117.7) |
| Female | 32 | 24.2 | 132.5 | (90.6-187.0) |  | Female | 40 | 36.2 | 110.6 | (79.0-150.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 138 | 168.5 | 81.9 | (68.8-96.8) |  |  |  |  |  |  |
| Female | 190 | 189.6 | 100.2 | (86.5-115.5) |  | Female | 60 | 60.8 | 98.8 | (75.4-127.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 54 | 40.1 | 134.7 | (101.2-175.8) |  | Male | 56 | 53.7 | 104.3 | (78.7-135.4) |
| Female | 11 | 11.8 | 93.1 | (46.4-166.6) |  | Female | 62 | 62.3 | 99.5 | (76.3-127.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 16 | 14.9 | 107.4 | (61.3-174.4) |  | Male | 495 | 503.8 | 98.3 | (89.8-107.3) |
| Female | 19 | 13.5 | 140.5 | (84.6-219.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 85 | 85.0 | 100.0 | (79.8-123.6) |  | Male | 36 | 36.1 | 99.8 | (69.9-138.1) |
| Female | 61 | 53.6 | 113.8 | (87.0-146.1) |  | Female | 24 | 24.5 | 97.8 | (62.7-145.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 22 | 23.2 | 94.9 | (59.4-143.7) |  | Male | 21 | 29.2 | 72.0 | (44.5-110.0) |
| Female | 9 | 7.9 | 113.9 | (52.0-216.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 70 | 65.0 | 107.6 | (83.9-136.0) |  | Male | 41 | 41.9 | 97.7 | (70.1-132.6) |
| Female | 54 | 53.0 | 101.9 | (76.6-133.0) |  | Female | 119 | 136.3 | 87.3 | (72.3-104.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 86 | 53.2 | 161.5 | (129.2-199.5) |  |  |  |  |  |  |
| Female | 21 | 19.3 | 109.1 | (67.5-166.8) |  | Female | 156 | 148.2 | 105.3 | (89.4-123.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 330 | 266.6 | 123.8 | (110.8-137.9) |  | Male | 2085 | 2029.7 | 102.7 | (98.4-107.2) |
| Female | 354 | 317.2 | 111.6 | (100.3-123.8) |  | Female | 2222 | 2311.3 | 96.1 | (92.2-100.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

357

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 4 | 6.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 1.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 3.2 | 190.2 | (69.4-413.9) |  | Male | 24 | 23.1 | 103.7 | (66.4-154.3) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 18 | 20.9 | 86.1 | (51.0-136.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

358

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 9.9 | 100.9 | (48.3-185.5) |  | Male | 6 | 7.0 | 85.7 | (31.3-186.6) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 11 | 6.1 | 179.0 | (89.2-320.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 9 | 6.4 | 141.6 | (64.6-268.8) |
| Female | 59 | 49.4 | 119.5 | (90.9-154.1) |  | Female | 4 | 6.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 5 | 2.5 | 196.2 | (63.2-457.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 12.1 | 181.9 | (113.9-275.4) |  |  |  |  |  |  |
| Female | 11 | 13.2 | 83.2 | (41.5-148.9) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 2.9 | 208.7 | (76.2-454.2) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 45 | 37.3 | 120.6 | (88.0-161.4) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 5 | 9.0 | 55.7 | (18.0-130.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 6 | 11.1 | 54.2 | (19.8-117.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 17.9 | 94.7 | (55.1-151.7) |  | Male | 158 | 143.2 | 110.3 | (93.8-128.9) |
| Female | 15 | 21.7 | 69.2 | (38.7-114.2) |  | Female | 149 | 162.1 | 91.9 | (77.8-107.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

359

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 49 | 49.4 | 99.1 | (73.3-131.1) |  | Male | 41 | 27.3 | 150.2 | (107.7-203.7) |
| Female | 25 | 17.7 | 140.9 | (91.1-208.0) |  | Female | 50 | 19.4 | 257.9 | (191.4-340.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.6 | 75.8 | (24.4-176.9) |  | Male | 8 | 9.0 | 89.3 | (38.4-175.9) |
| Female | 9 | 5.8 | 154.0 | (70.3-292.3) |  | Female | 7 | 7.6 | 92.6 | (37.1-190.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 23 | 24.3 | 94.8 | (60.1-142.2) |
| Female | 178 | 154.6 | 115.1 | (98.8-133.3) |  | Female | 23 | 22.3 | 103.1 | (65.4-154.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 16.6 | 126.4 | (78.2-193.2) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 8 | 9.0 | 89.1 | (38.4-175.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 47.6 | 88.3 | (63.6-119.4) |  |  |  |  |  |  |
| Female | 45 | 51.1 | 88.1 | (64.3-117.9) |  | Female | 11 | 14.1 | 77.9 | (38.8-139.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 11.2 | 168.9 | (101.7-263.8) |  | Male | 18 | 16.0 | 112.4 | (66.6-177.7) |
| Female | 6 | 3.3 | 181.2 | (66.2-394.4) |  | Female | 14 | 17.8 | 78.6 | (42.9-131.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 147 | 127.9 | 114.9 | (97.1-135.1) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 20.5 | 68.2 | (37.2-114.4) |  | Male | 8 | 10.7 | 74.9 | (32.2-147.5) |
| Female | 10 | 13.3 | 75.1 | (35.9-138.1) |  | Female | 7 | 6.7 | 105.0 | (42.1-216.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 31 | 17.1 | 181.0 | (123.0-256.9) |  | Male | 11 | 7.5 | 146.7 | (73.1-262.4) |
| Female | 18 | 12.7 | 142.1 | (84.2-224.6) |  | Female | 11 | 21.4 | 51.3 | (25.6-91.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 13.4 | 134.7 | (79.8-212.9) |  |  |  |  |  |  |
| Female | 8 | 5.1 | 156.8 | (67.5-308.9) |  | Female | 32 | 34.8 | 92.0 | (62.9-129.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 86 | 82.6 | 104.1 | (83.3-128.6) |  | Male | 592 | 548.8 | 107.9 | (99.4-116.9) |
| Female | 93 | 90.5 | 102.8 | (82.9-125.9) |  | Female | 610 | 565.4 | 107.9 | (99.5-116.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

360